OncoMatch/Clinical Trials/NCT06988488
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Is NCT06988488 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Elranatamab and Mezigdomide for multiple myeloma.
Treatment: Elranatamab · Mezigdomide · Dexamethasone — The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-myeloma therapy
relapsed and refractory multiple myeloma (RRMM) treated with 2 to 4 prior lines of anti-myeloma therapy (Phase 1) or 1 to 3 prior lines of anti-myeloma therapy (Phase 2)
Cannot have received: mezigdomide (mezigdomide)
Prior treatment with mezigdomide.
Cannot have received: T cell engager
Prior treatment with T cell engaging or T cell engager (TCE).
Cannot have received: BCMA-targeting therapy
Exception: autologous BCMA-targeted CART-cell therapy > 6 months from the start of study therapy
Prior treatment with B cell-maturation antigen (BCMA)-targeting therapy, with the exception of participants who have received autologous BCMA-targeted CART-cell therapy> 6 months from the start of study therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- Yale New Haven Hospital-Smilow Cancer Center · New Haven, Connecticut
- Hackensack University Medical Center · Hackensack, New Jersey
- University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify